The Latest Breaking News from Medical – Pharmaceuticals

Pfizer’s (PFE) co-developed COVID-19 vaccine booster for children, which recently got Emergency Use Authorization from the U.S. FDA, could boost its share price. The stock had witnessed significant attention during the pandemic and could still be worth owning. Let’s discuss this in detail….

Healthcare giant (MRK) has gained more than 20% in 2022. Moreover, it pays handsome dividends to its shareholders. And its attractive valuations and robust profitability make it a better Buy than its peers. Let's discuss this in detail….

Amid the highly uncertain market conditions, investors must look for stocks with ample room for growth and better stability. Biopharmaceutical major Pfizer’s (PFE) products remain in demand irrespective of economic cycles. Given its robust financials, discounted valuation, and high profitability, it could be wise to invest in this defensive stock.…

August CPI figures indicate that inflation is yet to be controlled, and the Fed might launch another significant interest rate hike next week. As recessionary fears loom over the economy, it might be ideal for seniors to invest in the fundamentally sound stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and…

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

The wide use of cannabis for recreational activities and its increased medicinal use has helped the market gain traction over the past years. However, with legalization barriers worldwide, this industry is in an odd limbo in which consumption flourishes, but penalties and taxes still prevail. Given the backdrop, it should…

Shares of the biopharmaceutical company Summit Therapeutics (SMMT) gained over the past few days, driven by significant insider buying. However, as the stock is down more than 55% this year, would it be wise to invest in the stock now? Read on to find out….

Pharmaceutical giant Pfizer’s (PFE) omicron-targeted booster doses could soon be authorized this fall. The company has benefited largely from the pandemic and its vaccine rollouts. Now let’s find out if PFE is a Buy now as it prepares to roll out its booster doses….

Axsome Therapeutics (AXSM) and Johnson & Johnson (JNJ) are expected to benefit from the rising number of chronic diseases and continued technological advancements in the pharmaceutical sector. But which of these stocks is a better buy now? Read more to find out….